SLC35B3

Across TCGA pan-cancer cohorts, SLC35B3 mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of SLC35B3’s most consistent transcriptional readouts.

The strongest signal is observed in lung adenocarcinoma (LUAD), where SLC35B3 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types SLC35B3 is over-expressed in tumor, although a few such as PDAC show the opposite, repressed pattern.

LUAD, LSCC, and PDAC are the cancer types where SLC35B3 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SLC35B3 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LUAD	Female	II,III,IV	+0.710	<.001	8	view →
LSCC	All	All	+0.311	<.001	8	view →
PDAC	All	All	−0.463	<.001	6	view →
CCRCC	All	IV	+0.366	.015	4	view →
OV	All	All	+0.693	<.001	2	view →
HNSC	All	IV	+0.398	.013	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

SLC35B3–LUAD

Open the LUAD breakdown →